Yoshito Nakanishi

Yoshito Nakanishi

Chugai Pharmaceutical Co., Ltd. - Tokyo / Japan
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4970624
person_outline Yoshito Nakanishi's MOST POPULAR ARTICLES
1-) The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitorY Nakanishi, N Akiyama, T Tsukaguchi, T Fujii, K Sakata, H Sase, T Isobe, ...Molecular cancer therapeutics 13 (11), 2547-2558, 20141242014
2-) Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune ActivationM Kamata-Sakurai, Y Narita, Y Hori, T Nemoto, R Uchikawa, M Honda, ...Cancer discovery 11 (1), 158-175, 2021762021
3-) Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3–BAIAP2L1Y Nakanishi, N Akiyama, T Tsukaguchi, T Fujii, Y Satoh, N Ishii, M AokiMolecular cancer therapeutics 14 (3), 704-712, 2015752015
4-) Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110βY Nakanishi, K Walter, JM Spoerke, C O\'Brien, LY Huw, GM Hampton, ...Cancer research 76 (5), 1193-1203, 2016732016
5-) YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene AmplificationN Hamanaka, Y Nakanishi, T Mizuno, K Horiguchi-Takei, N Akiyama, ...Cancer research 79 (22), 5734-5745, 2019542019